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Bioassay Bashing Is Bad
Science
The Spheres of Influence, “Assessing Assays”
(Schmidt 2002), in the May 2002 issue of
EHP criticizes the National Toxicology
Program rodent bioassay (NTPRB) without
discussing its importance in regulation and
public health. The Spheres article (Schmidt
2002) does not express concern for the valid-
ity of alternative transgenic methods pro-
posed to replace the NTPRB for detecting
carcinogens. By focusing on the limitations of
the NTPRB without mentioning limitations
of transgenic alternatives, Spheres creates the
impression that transgenics are superior.
Attempting to supplant the rodent bioassay
with various mutation tests, DNA repair
tests, cell transformation tests, and many oth-
ers is a history of failure (Johnson 2000,
2001; Johnson and Snell 1986; Rall et al.
1987). The Spheres  article (Schmidt 2002)
does not provide any evidence to persuade us
that transgenics will change that history. 
To illustrate bias, Spheres (Schmidt
2002) states that 
Rodent models used to test potential carcinogens
are by their nature “wrong” because they merely
simulate the response of the real target species—
humans.
However, the Spheres article (Schmidt
2002) gives no evidence to explain why
rodent models are “wrong,” or why by simi-
lar reasoning transgenics would not also be
wrong. NTPRB results sometimes provide
and precede the same indication of carcino-
genicity found in humans (Huff, 1993;
IARC, 2002; Tomatis, 1979). These
responses in rodents have proven to be accu-
rate, that is, not “wrong.” 
Also, according to a statement attributed
to James MacDonald at Shering Plow
Research Institute (Kenilworth, NJ), conven-
tional rodent models predict human cancer
no better than “a flip of the coin.” This state-
ment is disingenuous. Although the NTPRB
has identified human carcinogens, no one
knows for sure with what accuracy it will
predict future human carcinogens. If the
“coin flip” notion were true, then it would
be just as true for transgenics. However, no
reasonable person would suggest replacing
established methods to identify carcinogens
with “coin flips.” Importantly, few human
carcinogens have been tested thoroughly in
any model, and very few known human
noncarcinogens are available to evaluate the
negative responses in the model systems. 
The Spheres article (Schmidt 2002)
concludes with a quotation by Samuel
Cohen: “My hope is that this is the first
step toward getting rid of the two-year
bioassay altogether.” Obviously, Cohen
ignores the fact that the rodent bioassay is
an accepted regulatory standard and before
we “get rid of it,” an alternative method must
be developed and validated. 
Validation is a rigorous scientific process
whereby the performance of a model is com-
pared against the performance of accepted
methods. Validation is governed by the
Interagency Coordinating Committee on
the Validation of Alternative Methods
(ICCVAM 2002). Although some people
may express a preference for transgenic alter-
natives, no new method will gain regulatory
acceptance without ICCVAM. In the case
of rodent carcinogenesis tests, until pro-
posed replacements are validated, regulatory
agencies will be expected to use the standard
bioassay for identifying carcinogenic agents. 
The NTPRB represents a serious effort
to evaluate agents by essentially one stan-
dard protocol: two species (usually Fischer
rats and B6C3F1 mice), both sexes, expo-
sures lasting for two-thirds of the lifetime,
and multiple doses including the maximum
tolerated amount (Bucher 2000; Chhabra
et al. 1990; Fung et al. 1995; Haseman et
al. 2001; Huff 1999a, 1999b; Huff and
Haseman 1991). Virtually all tissues are
examined for tumors. This standard proto-
col has been adopted throughout the world. 
Although criticism has been leveled
against the bioassay (Ames and Gold 1990,
1997; Johnson 1999, 2000), some of it has
been misguided (Tomatis et al. 2001). While
questions of exposure levels and numbers of
animals have been raised (Johnson 2002),
these issues are not necessarily relevant for all
of the > 500 rodent studies that have been
done. For example, methylene chloride was
tested at concentrations to which workers are
exposed; butadiene at levels 150 times below
the Occupational Safety and Health
Administration standard (Huff et al. 1985;
Melnick and Huff 1992); benzene at concen-
trations near those found in gasoline (Huff et
al. 1989); dibromoethane at or below con-
centrations found in grain silos (Huff
1983b); tetranitromethane at levels found in
the munitions industry (Bucher et al. 1991);
and dibromochloropropane at levels found in
manufacturing plants (Huff 1983a). Several
other chemicals may fit into this category
(Huff 1999a, 1999b; NTP 2002).
When transgenic models are contem-
plated as replacements for standard rodent
systems, many of the same uncertainties arise,
and effects of dose, numbers of animals per
dose group, duration, routes of administra-
tion, and genotype are generally unknown. In
the case of transgenics, however, we also need
to know to what extent the power of detec-
tion may be altered compared to that pro-
vided by the NTPRB. For example, would a
suggested 6-month study using 15 transgenic
mice per dose per group be adequate to
detect a rare, late-developing or weak tumor
response we find in the standard NTPRB
protocol? Even for the NTPRB, duration of
exposure might be lengthened to increase
sensitivity (Haseman et al. 2001; Maltoni
1995), especially for late-appearing carcino-
genic effects (Soffretti et al. 2002).
For transgenic models, standards for
practically all experimental variables remain
under debate, and few comparisons between
the NTPRB and transgenics have been
made using the same chemicals. We have
much less experience with transgenic models
than we have with the NTPRB. Background
control tumor rates in transgenic systems are
only now becoming sufficiently well known
for comparative evaluation. A transgene may
alter responsiveness to different classes of
chemicals. Thus, a transgene may make a
system more sensitive for detecting one
chemical class or tumor type, and less sensi-
tive for another. Also, statistical false posi-
tives and false negatives, investigated in the
NTPRB (Haseman and Elwell 1996), have
not been explored in transgenics. 
The question of how to predict human
carcinogens more effectively would benefit
from fundamental research. The number of
genes contributing to increases or decreases
in susceptibility to the carcinogenic effect of
one chemical or another is unknown. In
order for one or a few transgenic models to
be able to accurately predict which chemi-
cals will be carcinogenic and which will not,
the number of genes that actually determine
susceptibility to chemical carcinogens in
human populations must necessarily be
quite small. However, the number and vari-
ety of genes could be large, and different
genes are likely involved in carcinogenicity
of different chemicals. Conceivably, one-half
or more of the genome could be involved in
carcinogenic responses. Until we better
appreciate the number and kind of geno-
types involved in carcinogenic responses,
our understanding of what a carcinogen is
will remain incomplete and how we manage
carcinogenic risks in our environment
uncertain. The need for fundamental
research is not a reason to change existing
prevention strategies; however, results of
that research could lead to future changes.
Advocates of transgenic models do not seem
to realize the importance of fundamental
research and thus may repeat errors made in
development of conventional rodent assays.
Transgenics are not a panacea for avoid-
ing uncertainties associated with rodent
bioassays (Johnson 2001). Because of trans-
gene-specific and chemical-specific enhanced
sensitivity, negative results in transgenics
may only mean that the “correct” transgene
was not used. Positive results may only
reflect hypersensitivity not found in humans.
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virtually limitless. Therefore, particular
models, such as the mouse embryonic zeta-
globin promoter fused to activated v-Ha-ras
(Tg.AC), may or may not show the appro-
priate response to a given chemical.
Furthermore, having additional responses
from other similarly uncertain indicators
will not help differentiate carcinogens from
noncarcinogens.
Regardless of some uncertainties, the
NTPRB is the accepted regulatory standard
currently being used to protect worker
safety and public health from carcinogens
(e.g., Huff 1999a, 1999b; Maltoni 1995;
Rall 2000; Tomatis et al. 2001; Tomatis
and Huff 2001, 2002). Transgenic models
must demonstrate equal or better perfor-
mance before they can be accepted as
replacements. 
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“Bioassay Bashing Is Bad
Science”: Cohen’s Response
Thank you for the opportunity to respond to
the comments made by Johnson and Huff
regarding the article assessing alternative
assays, which appeared in the May 2002
issue of EHP (Schmidt 2002). In the com-
ments that I made to Schmidt, it was not my
intent to bash the bioassay. Instead, it was
my intent that the bioassay be put in per-
spective, which is why I used the quote from
George Box indicating that all models are
wrong, but that some are useful. Clearly, the
2-year bioassay has been useful. The diffi-
culty is that, like all models, it is not perfect.
There are innumerable examples now of
chemicals that have been identified as car-
cinogenic in the rat and/or mouse that for a
variety of reasons are now considered not to
be carcinogenic to humans, either because of
qualitative differences in the mechanism of
action or, more commonly, striking quanti-
tative differences between species or between
exposures. The mechanism of action for cer-
tain rodent chemical carcinogens has been
identified in animal models and is not rele-
vant to the human situation. Examples
include α2u-globulin–related male rat renal
tumors (d-limonene), luteinizing hormone
abnormalities and the induction of breast
tumors in Sprague-Dawley rats (atrazine),
and calcium phosphate-containing precipi-
tate-related bladder tumors in rats (sodium
saccharin, sodium ascorbate). Others are
likely to be identified. This has led to the
delisting of sodium saccharin from the
National Toxicology Program’s (NTP) con-
gressionally mandated list of carcinogens.
Also removed from that list of carcinogens
was ethyl acrylate, a rat forestomach carcino-
gen for which much of the research was per-
formed at the NTP. The International
Agency for Research on Cancer has also
made an effort to reclassify chemicals based
on mechanism of action, and has done so for
a variety of chemicals and known mecha-
nisms. In addition to qualitative differences,
numerous quantitative differences exist
between carcinogenic effects in rodents and
humans, such as urinary calculi (melamine,
fosetyl-Al) and rat thyroid tumors (sulfamet-
hazine), suggesting no potential carcinogenic
risk to humans.
The intent of these studies is to try to
predict human carcinogenicity. The same is
true for the alternative models. I agree with
Johnson and Huff in their statement that 
The question of how to predict human carcinogens
more effectively would benefit from fundamental
research.
The 2-year bioassay is useful and is likely to
remain so for several years to come. However,
it is imperfect, and additional research is
needed not only to come up with better
screening models but also to provide the
necessary mechanism of action information
that is needed to interpret the results in the
screening assays.
The alternative models involving trans-
genic and knockout mice have many of the
same imperfections as the 2-year bioassay.
Johnson and Huff are correct in indicating
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evaluated and defined. Nevertheless, it is
already clear that some of these alternative
models can provide useful information that is
as reliable as the standard 2-year mouse bioas-
say. The U.S. Food and Drug Administration
and the European authorities are already uti-
lizing results from these assays in their evalua-
tion of pharmaceuticals.
The 2-year bioassay is nearly 40 years
old. It has proven useful and will continue to
do so. However, the intent is not to deter-
mine carcinogenicity in rats or mice, but
ultimately to accurately predict carcinogenic-
ity in humans. There is no doubt that some-
time in the future assays will be developed
that are better able to make these predictions
than the 2-year bioassay. The development
of the alternative animal models that were
discussed in the Spheres of Influence article
(Schmidt 2002) is a step in that direction.
Additional research is required, but the 2-
year bioassay should not be viewed as sacro-
sanct nor as the gold standard by which
other assays are to be validated. Appropriate
validation is the comparison with human
carcinogenesis.
Samuel M. Cohen
Department of Pathology and Microbiology
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“Bioassay Bashing Is Bad
Science”: MacDonald’s
Response
I appreciate the opportunity to respond to
the letter from Johnson and Huff on the
May 2002 Spheres of Influence, “Assessing
Assays” (Schmidt 2002). Several points
brought up by Johnson and Huff need to be
clarified and some need to be challenged:
It is disappointing that Johnson and
Huff see this article as “bashing the bioas-
say.” Criticism of the rodent bioassay as per-
formed by the National Toxicology
Program (NTP) does not imply that contri-
butions to human hazard identification and
risk assessment have not been made by this
methodology over the 40 years that it has
been employed, but is it “bad science” to
seek ways to improve this process with new
technology? It would seem that, as con-
cerned scientists, our debate should not cen-
ter around which assay is “better” but rather
how we can best identify and use data from
a variety of sources to improve our ability to
prospectively identify chemicals that pose
human risk.
The Spheres article (Schmidt 2002)
described in some detail the efforts to assess
the response to a list of well-characterized
chemicals in several newly developed trans-
genic and knockout mice. Although many
groups are evaluating these assays now, the
efforts of the International Life Sciences
Institute/Health and Environmental Sciences
Institute (ILSI/HESI) Alternatives to
Carcinogenicity Testing Committee were
highlighted in the article. The specific intent
of this effort by the ILSI/HESI was to gain
experience with these newer assays in a care-
fully controlled experimental manner. The
goal was not to replace the bioassay, as
Johnson and Huff seem to suggest, but
rather to see how (or if) data from these
assays could be used in the process of assess-
ing human risk of cancer from chemical
exposure (Cohen et al. 2001). Research with
these newer assays in the HESI initiative was
focused on improving the process of human
hazard identification and the use of the
information from these assays in a global
weight-of-evidence approach to risk assess-
ment; it clearly was not focused on simply
replacing one method with another. 
Johnson and Huff reacted to my sugges-
tion that conventional rodent models pre-
dict human cancer no better than “a flip of
the coin.” Perhaps this was a bit casual and
even provocative, but is it really disingenu-
ous? There is no argument that the rodent
bioassay can detect human carcinogens. The
problem is that it also identifies many other
chemicals that are generally not regarded as
human carcinogenic risks (Cohen and
Ellwein 1991; MacDonald et al. 1994;
McClain 1994). The data from the use of
this assay are clear: approximately 50% of
the chemicals tested in either the rat or
mouse bioassay have yielded positive results
(Contrera et al. 1997; Davies and Monro
1995; Gold et al. 1984; Van Oosterhout et
al. 1997). Although this number has come
down as fewer suspected carcinogens (geno-
toxic agents) are tested in the NTP Rodent
Bioassay Program (Fung et al. 1995), there
is still a very high rate of positive outcomes.
Unless we are expecting a wave of carcino-
gens to be identified in the next 10–15 years
from extensive human use of these agents,
we can consider most of these responses as
false-positive results. This may not be quite
a flip of the coin, but it is not a great
improvement for the significant expenditure
of time and money for this assay.
Johnson and Huff state in their letter
that alternative assays for carcinogen hazard
identification such as the transgenic assays
cannot be accepted for regulatory use with-
out validation through a process such as the
Interagency Coordinating Committee on
the Validation of Alternative Methods
(ICCVAM). Two important points should
be mentioned here. First, the rodent bioas-
say, which is held up as the “gold standard,”
has never been validated through a rigorous
process such as that proposed by ICCVAM.
Given some of the concerns raised above,
one wonders if even this well-established
assay could satisfy our current demands for
validation. Second, the International
Conference on Harmonization has pub-
lished guidelines (International Conference
on Harmonization 1995) that clearly state
that, for pharmaceutical chemicals, the
appropriate use of alternative assays such as
transgenic or knock-out mice can suffice to
replace the use of one or another of the
rodent bioassays. As this practice is occur-
ring with pharmaceuticals in the approval
process, we will come to better understand
the utility (if not the validity) of these data
just as we did with the rodent bioassay.
In their letter, Johnson and Huff point
out an important, and appropriate, criticism
of the current transgenic and knock-out
mouse models: there are several protocol
issues that need to be addressed. I partici-
pated in the ILSI/HESI initiative for about 6
years as this group struggled to understand
how best to apply some of the then new
assays to the problem of human hazard iden-
tification, specifically in the area of pharma-
ceutical chemicals. As the results from this
effort suggest, data from these alternative
assays can be used appropriately, but several
important questions remain to be answered.
(MacDonald et al. 2001) Whether these are
being adequately addressed with currently
ongoing research or whether additional,
focused research efforts would be appropriate
is the subject of ongoing discussions with the
HESI group and a broad cross-section of
stakeholders. It is again important to empha-
size that the focus of this effort was not and
is not replacement of the rodent bioassay,
but a better understanding of how data from
newer models might aid in our ability to
detect potential human carcinogens. 
Johnson and Huff also point out appro-
priately that additional fundamental
research on the genetics of human cancer
has the potential to improve our ability to
reliably detect human carcinogens before
these chemicals are released into our envi-
ronment. Studying transgenic animals and
carefully assessing whether the nature of the
transgene alters the response to particular
chemicals should not be construed as failing
to realize the importance of fundamental
research, but rather as a central component
of this important process. 
Assessment of the human risk of cancer
is perhaps one of the most difficult tasks in
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and appropriate information from a broad
variety of sources should be brought to bear
on this important question. Although data
from the rodent bioassay have made impor-
tant contributions in the past, we continue
to compare the performance of new assays
to this so-called standard. If we are trying to
improve how we assess human risk of cancer
from chemical exposure, we need to change
this focus on how well we predict cancer in
rats and mice.
James S. MacDonald
Drug Safety and Metabolism
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Use of A-Bomb Survivor
Studies as a Basis for Nuclear
Worker Compensation
In the Spheres of Influence article in the
July issue of EHP, Parascandola (2002) pre-
sented our concerns about the validity of
extrapolating cancer risks from studies of
A-bomb survivors to nuclear workers as a
matter of differences in dose rate between
the two populations. Our primary critiques
of using A-bomb data, however, concern
biases that arise from selective survival and
dose misclassification (Wing et al. 1999),
issues that are not mentioned. Stewart
(1985, 1997, 2000) presented evidence of
dose- and age-related selective survival in
the Japanese cohort assembled for cancer
studies 5 years after the nuclear bombing of
Hiroshima and Nagasaki. This evidence is
in concordance with basic biological princi-
ples of heterogeneity in susceptibility and
may help explain the inability of A-bomb
survivor studies to detect the impacts of in
utero radiation exposures on childhood can-
cers, effects that have been demonstrated
repeatedly in low dose studies (Doll and
Wakeford 1997; McMahon 1962; Stewart
et al. 1956). Age-related selective survival
also helps to explain the reported decrease
in radiation–cancer dose response among
A-bomb survivors exposed at older ages, an
observation that deviates from expectations
based on the increased sensitivity of older
adults to other physical, chemical, and bio-
logical agents, evidence of age-related
decline in DNA repair capacity, and evi-
dence from some studies of nuclear workers
(Richardson et al. 2001; Wing 2000).
Epidemiologic studies depend on accu-
rate exposure classification for valid dose–
response estimation. In addition to selective
survival in a population subjected to nuclear
attack and subsequent devastation of public
health infrastructure, radiation–cancer
dose–response estimates from A-bomb stud-
ies are further affected by a lack of individual
dose measurements and the use of dose
reconstruction based on interviews con-
ducted in an occupied nation by a scientific
team funded and directed by the U.S. gov-
ernment (Wing et al. 1999). The ability to
elicit accurate information on location, posi-
tion, and shielding was affected not only by
traumatization of the survivors and their
domestic stigmatization but by their distrust
of medical teams working under occupation
forces (Lindee 1994). 
As Parascandola (2002) noted, we
believe that findings from carefully con-
ducted epidemiologic studies of badge-
monitored nuclear workers exposed to
chronic, low-level ionizing radiation should
be considered in implementation of the
Energy Employees Occupational Illness
Compensation Program Act. Medical prac-
tices regarding exposures of pregnant
women to diagnostic X rays were changed
decades ago on the basis of low-dose stud-
ies, even though their findings were not
predicted from studies of A-bomb survivors.
The question today is, will A-bomb studies
continue to dictate estimates of cancer risks
in adulthood, despite evidence of bias and
the availability of alternative epidemiologic
data? The large number of highly exposed
survivors in the study, cited as a major
strength, may actually be a weakness if it
encourages scientists and policy makers to
confuse statistical precision with valid dose–
response estimates that depend on an
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Correspondence
Correction
In the October issue of EHP, the list of Children’s Environmental Health Centers
[EHP 110:A571 (2002)] included an incorrect Web address for the Columbia
University Center for Children's Environmental Health. The correct Web address is
www.ccceh.org